

REMARKS

Information Disclosure Statement

Applicants request that the Examiner return a copy of the second page of the Form PTO-1449 received by the Patent Office on October 19, 2001, on which the Examiner has initialed all of the boxes corresponding to all of the references listed on the form. A copy of the Form PTO-1449 was returned to the Applicants with the Office action mailed from the Patent Office on March 24, 2003, but the Examiner had only initialed the boxes on the first page. As this document was originally timely filed (copy of PTO-stamped return receipt postcard enclosed), Applicants respectfully submit that no fee is required. However, should a fee be required, Applicants hereby authorize the Director to charge Deposit Account No. 20-0531, as necessary. A copy of the second page of the Form PTO-1449 is enclosed for the Examiner's convenience.

Election/Restrictions

The Office has required Applicants to elect one of two perceived inventive concepts to which the claims must be restricted: Claims 91-94 (Group I) drawn to a chimeric NPY5 receptor in which the third intracellular loop domain is substituted by the loop domain of an NPY1 receptor, classified in class 530, subclass 350+, and claims 95-98 (Group II), drawn to a chimeric NPY5 receptor in which the C-terminal domain is substituted by the C-terminal domain of an NPY1 receptor; classified in class 530, subclass 350+.

Applicants hereby elect, with traverse, the claims of **Group II**, namely, claims **95-98**. Applicants respectfully traverse the restriction requirement insofar as the Groups are classified in the same class and subclass and a search for publications relating to either Groups I or II would reveal publications relating to the other Group and, thus, would not impose a serious burden on the Examiner. Accordingly, Applicants respectfully request that the restriction requirement be reconsidered and withdrawn.

Applicants reserve the right to pursue any non-elected claims in one or more related applications if the restriction requirement is maintained.

Applicants acknowledge the reminder regarding the need to review inventorship and will adjust it if needed upon the cancellation of any non-elected claims.

CONCLUSION

Applicants respectfully request that the application now proceed promptly to examination.

Very truly yours,



Daniel A. Wilson
Attorney for Applicants
Testa, Hurwitz, & Thibeault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

Date: December 9, 2004
Reg. No. 45,508

Tel. No.: (617) 248-7226
Fax No.: (617) 248-7100


3153212

INFORMATION DISCLOSURE

OCT 19 2001 STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
U 013223-9	09/771,956
APPLICANT	
Mich I Benn et al. KINRADE, et al.	
FILING DATE	GROUP
01/29/2001	1646



REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA						RECEIVED TECH CENTER 1600 2/29/2001 NO

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
	AB					

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

AC	Logan, et al. "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 81, p. 3655-3659, (1984)
AD	Lowy, I., et al. "Isolation of Transforming DNA: Cloning the Hamster apt Gene" <i>Cell</i> , Vol. 22, p. 817-823, (1980)
AE	Mery, L., et al. "The NH2-terminal Region of C5aR But Not That of FPR Is Critical for Both Protein Transport and Ligand Binding" <i>J. Biol. Chem.</i> , Vol. 269, No. 5, p. 3457-3463, (1994)
AF	Moyle, W.R., et al. "Leutropin/β-Adrenergic Receptor Chimeras Bind Choriogonadotropin and Adrenergic ... Surface" <i>J. Biol. Chem.</i> , Vol. 266, No. 17, p. 10807-10812, (1991)
AG	Wahlestedt, C., et al. "Modulation of Anxiety and Neuropeptide Y-Y1 Receptors by Antisense Oligodeoxynucleotides" <i>Science</i> , Vol. 259, p. 528-531, (1993)
AH	Westfall, T.C., et al. "In Vitro Effects of Neuropeptide Y at the Vascular Neuroeffector Junction" <i>Ann. NY Acad. Sci.</i> , Vol. 611, p. 145-155, (1990)
AI	
AJ	
AK	
AL	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY